WallStSmart

Rambus Inc (RMBS)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Rambus Inc generates 179% more annual revenue ($721.15M vs $258.90M). RMBS leads profitability with a 31.9% profit margin vs -15.5%. RMBS earns a higher WallStSmart Score of 52/100 (C-).

RMBS

Buy

52

out of 100

Grade: C-

Growth: 5.3Profit: 9.0Value: 2.0Quality: 6.5
Piotroski: 4/9

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

RMBSSignificantly Overvalued (-84.5%)

Margin of Safety

-84.5%

Fair Value

$53.88

Current Price

$112.16

$58.28 premium

UndervaluedFair: $53.88Overvalued
ZEPPUndervalued (+48.6%)

Margin of Safety

+48.6%

Fair Value

$46.70

Current Price

$17.47

$29.23 discount

UndervaluedFair: $46.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

RMBS2 strengths · Avg: 10.0/10
Profit MarginProfitability
31.9%10/10

Keeps 32 of every $100 in revenue as profit

Operating MarginProfitability
34.3%10/10

Strong operational efficiency at 34.3%

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

RMBS4 concerns · Avg: 2.5/10
Price/BookValuation
8.7x4/10

Trading at 8.7x book value

PEG RatioValuation
3.802/10

Expensive relative to growth rate

P/E RatioValuation
53.7x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-1.8%2/10

Earnings declined 1.8%

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$247.54M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : RMBS

The strongest argument for RMBS centers on Profit Margin, Operating Margin. Profitability is solid with margins at 31.9% and operating margin at 34.3%.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : RMBS

The primary concerns for RMBS are Price/Book, PEG Ratio, P/E Ratio. A P/E of 53.7x leaves little room for execution misses.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

RMBS profiles as a mature stock while ZEPP is a hypergrowth play — different risk/reward profiles.

ZEPP carries more volatility with a beta of 1.77 — expect wider price swings.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

Monitor SEMICONDUCTORS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

RMBS scores higher overall (52/100 vs 41/100), backed by strong 31.9% margins. ZEPP offers better value entry with a 48.6% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Rambus Inc

TECHNOLOGY · SEMICONDUCTORS · USA

Rambus Inc. offers semiconductor products in the United States, Taiwan, South Korea, Japan, Europe, Canada, Singapore, Asia, and internationally. The company is headquartered in San Jose, California.

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?